250 related articles for article (PubMed ID: 25137243)
1. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.
Pinkerton JV; Joffe H; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
Menopause; 2015 Jan; 22(1):50-8. PubMed ID: 25137243
[TBL] [Abstract][Full Text] [Related]
2. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
Capriglione S; Plotti F; Montera R; Luvero D; Lopez S; Scaletta G; Aloisi A; Serra GB; Angioli R
Gynecol Oncol; 2016 Dec; 143(3):584-588. PubMed ID: 27751589
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials.
Riemma G; Schiattarella A; La Verde M; Zarobbi G; Garzon S; Cucinella G; Calagna G; Labriola D; De Franciscis P
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31480427
[No Abstract] [Full Text] [Related]
4. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
Simon JA; Portman DJ; Kaunitz AM; Mekonnen H; Kazempour K; Bhaskar S; Lippman J
Menopause; 2013 Oct; 20(10):1027-35. PubMed ID: 24045678
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
Portman DJ; Kaunitz AM; Kazempour K; Mekonnen H; Bhaskar S; Lippman J
Menopause; 2014 Oct; 21(10):1082-90. PubMed ID: 24552977
[TBL] [Abstract][Full Text] [Related]
6. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis.
Wei D; Chen Y; Wu C; Wu Q; Yao L; Wang Q; Wang XQ; Yang KH
BJOG; 2016 Oct; 123(11):1735-43. PubMed ID: 27062457
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
Stearns V; Beebe KL; Iyengar M; Dube E
JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation.
Soares CN; Joffe H; Viguera AC; Petrillo L; Rydzewski M; Yehezkel R; Somley B; Cohen LS
Am J Med; 2008 Feb; 121(2):159-162.e1. PubMed ID: 18261506
[TBL] [Abstract][Full Text] [Related]
9. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine.
Simon JA; Chandler J; Gottesdiener K; Lazarus N; He W; Rosenberg E; Wagner JA; Denker AE
Menopause; 2014 Sep; 21(9):938-44. PubMed ID: 24569618
[TBL] [Abstract][Full Text] [Related]
10. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
Weber L; Thacker HL
Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
[TBL] [Abstract][Full Text] [Related]
11. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
Simon JA; Gaines T; LaGuardia KD;
Menopause; 2016 Nov; 23(11):1214-1221. PubMed ID: 27760081
[TBL] [Abstract][Full Text] [Related]
12. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.
Ensrud KE; Joffe H; Guthrie KA; Larson JC; Reed SD; Newton KM; Sternfeld B; Lacroix AZ; Landis CA; Woods NF; Freeman EW
Menopause; 2012 Aug; 19(8):848-55. PubMed ID: 22433978
[TBL] [Abstract][Full Text] [Related]
13. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
14. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.
Joffe H; Crawford S; Economou N; Kim S; Regan S; Hall JE; White D
Sleep; 2013 Dec; 36(12):1977-85. PubMed ID: 24293774
[TBL] [Abstract][Full Text] [Related]
15. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.
Joffe H; Soares CN; Petrillo LF; Viguera AC; Somley BL; Koch JK; Cohen LS
J Clin Psychiatry; 2007 Jun; 68(6):943-50. PubMed ID: 17592922
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
[TBL] [Abstract][Full Text] [Related]
17. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
[TBL] [Abstract][Full Text] [Related]
18. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
19. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
Soares CN; Joffe H; Rubens R; Caron J; Roth T; Cohen L
Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
[TBL] [Abstract][Full Text] [Related]
20. A Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
Fantasia HC
Nurs Womens Health; 2016; 20(5):511-518. PubMed ID: 27719781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
